Drug Trial Radar · NCT00989716
The Efficacy of Nitric Oxide in Stroke (ENOS) Trial
Last checked: Nov 19, 2026Latest source record: Jul 24, 2012 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,500
Planned (sponsor's estimate)
Start
Jul 2001
Primary completion
Oct 2013
Study completion Oct 2013
Sponsor
- Lead sponsor
- University of NottinghamAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Oct 5, 2009
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (participant)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Nitric oxide is a multimodal candidate treatment for acute stroke having a number of properties which may be beneficial in acute stroke, including lowering blood pressure, causing cerebral vasodilation, and improving central and systemic haemodynamics. Nitric oxide donors are effective in experimental stroke and pilot studies in patients suggest that one, glyceryl trinitrate, can be delivered easily in a transdermal preparation. Around half of all patients admitted with acute stroke are taking antihypertensive therapy immediately prior to their stroke. No data exist as to whether it is beneficial or safe to stop or continue this treatment during the acute phase. ENOS is a prospective, international, multicentre, randomised, parallel-group, blinded, controlled, collaborative, factorial trial designed to test two questions related to the management of blood pressure immediately post-stroke: 1. The safety and efficacy of nitric oxide, given as transdermal glyceryl trinitrate. 2. The safety and efficacy of stopping or continuing prior antihypertensive medication. Previously independent adult patients who are conscious and have residual limb weakness are eligible for enrollment. Central randomisation will be performed via the internet. Treatment is initiated within 48 hours of stroke onset and is given as daily glyceryl trinitrate patches for 7 days. A computed tomography (CT) scan is required within 7 days of randomisation. Early follow-up is performed locally over the 7 days of treatment, including blood pressure, early stroke events, and adverse events. Telephone central follow-up by the trial co-ordinating centre will be performed at 3 months. The primary outcome is combined death or dependency (modified Rankin Score \>2).
Conditions
- Stroke
Interventions
Transdermal glyceryl trinitrate patchDrug
5mg per day
Pre-stroke antihypertensivesDrug
Continue or stop pre-stroke anti-hypertensives
Primary outcomes
What the sponsor says the trial is designed to measure.
- Reduced death or dependency (modified Rankin score)Time frame: 90 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Nottingham University Hospitals NHS Trust (City Hospital)
Nottingham, Nottinghamshire, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.